GRN-1201 is a cancer vaccine aimed at boosting the body’s own immune response against tumor-associated antigens (TAAs) and activating tumor-specific T-cells. These infiltrate the tumor site and kill ...

A multicenter randomized Phase 2 trial (NCT02117024) is comparing the safety and effectiveness of a combination of viagenpumatucel-L and cyclophosphamide with traditional, single-agent chemotherapy in ...

Galinpepimut-S consists of four peptide chains, or small proteins that are designed to elicit a strong immune response against WT1. The immune system responds to Ganpepimut-S by building an army of ...

INO-5150 is an investigational cancer vaccine being developed by Inovio Pharmaceuticals as a possible treatment for prostate cancer. A dual antigen, synthetic DNA vaccine, it is produced based on the ...

MVA-BN Brachyury is a new cancer immunotherapy candidate being developed by Denmark’s Bavarian Nordic to help teach the body’s immune system to attack and destroy cancer cells. It is designed to ...

VBI-1901 is a vaccine against cytomegalovirus, or CMV. It is designed to kill glioblastoma and medulloblastoma tumor cells infected with CMV, as many are. The immune system already targets cells ...

VGX-3100 utilizes the patient’s own immune system to eliminate infections caused by HPV-16 and HPV-18 and to destroy pre-cancerous cells, or “lesions.” Two clinical studies have tested the therapeutic ...

GALE-301 is a cancer immunotherapy vaccine that Galena Biopharma is developing. It is in clinical trials that are looking at whether it can prevent the return of ovarian, endometrial, and breast ...

CRISPR/Cas9 is an experimental gene editing technique that potentially could be used in the treatment of a wide range of disorders caused by DNA mutations. It also is currently being investigated as a ...